The Most Innovative Healthcare AI Developments of 2019

wallstreetnation.com

Companies Mentioned:

Primary Exchange: OTCQB
Under the Symbol: CGNSF

The Most Innovative Healthcare AI Developments of 2019

Wednesday, January 9, 2019 9:50 AM

HOUSTON, TX / ACCESSWIRE / January 9, 2019 / Technology has changed in the blink of an eye.

Concepts that were nothing more than science fiction, such as artificial intelligence (AI) and machine learning are now quickly disrupting global industries with significant capabilities.

In fact, the limitless potential of AI alone is disrupting businesses, the way we conduct our affairs, and even the way financial institutions conduct high-frequency trading. It's impacting the way Salesforce.com, Microsoft, and Google do business.

Artificial Intelligence is even changing the way we look at healthcare in a big way.

The global healthcare AI market alone is expected to reach $6.16 billion by 2022, notes Healthcare Informatics. By 2026, experts estimate that AI applications could save the U.S. healthcare economy up to $150 billion, and help address 20% of unmet clinical demand. It could very well improve overall quality of patient care, prevent unnecessary medical costs and procedures while improving on diagnoses and treatment options.

It's no wonder 77% of healthcare executives are accelerating investments in AI, according to a New Vantage Partners survey.

As such disruptive technology makes its way into the healthcare sector, some of the top stocks to watch include Cognetivity Neurosciences Ltd. (CSE: CGN)(OTCQB: CGNSF), Globus Medical Inc. (NYSE: GMED), and BioXcel Therapeutics, Inc (NASDAQ: BTAI).

Cognetivity Neurosciences Ltd. (CGN)(CGNSF)was just featured a one of Forbes'top five young companies to watch in 2019. That comes shortly after the company raised $4.1 million to commercialize breakthrough AI technology to improve dementia diagnoses through the UK and potentially save $118,000 per patient.

The company's five-minute Integrated Cognitive Assessment (ICA) test uses AI and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. With early diagnosis of dementia, doctors can provide quicker treatment and monitoring to improve the lives of patients.

Cognetivity's CEO and Director, Dr. Sina Habibi, commented: "2019 has got off to a great start, with Cognetivity being featured in Forbes as one of five young companies making an impact on the world to watch In 2019. Our main goal is, and always has been for our technology to help as many people as possible, and this recognition is another fantastic endorsement of our aims and the company's enormous potential."

For More Information on Cognetivity Neurosciences Ltd., Click Here.

Globus Medical Inc. (GMED) is using AI technology for minimally invasive surgeries for example with the assistance of its ExcelsiusGPS robot.

"Surgeons and hospital administrators in the United States have shown tremendous levels of interest in ExcelsiusGPS since it first launched domestically at the end of 2017," said Dave Demski, CEO at Globus Medical. "Users have realized the system's ability to help advance patient care and provide tangible benefits for surgeons and their staff. As we begin to scale our efforts abroad, we have seen similar levels of enthusiasm within the international surgeon community and look forward to the continued adoption of ExcelsiusGPS into these markets."

For More Information on Globus Medical Inc., Click Here.

Clinical stage biopharmaceutical company, BioXcel Therapeutics, Inc (BTAI) uses AI technologies to design new medications for immune-oncology needs. In fact, the company was just granted Fast Track Designation for its investigational drug BXCL501 by the US FDA.

Dr. Vimal Mehta, Chief Executive Officer of BTI, commented, "Fast track designation for BXCL501 highlights FDA's recognition of our investigational therapy as a possible treatment for acute agitation associated with schizophrenia, bipolar disorder and dementia. This regulatory milestone will help facilitate clinical development and expedite regulatory review of BXCL501, bringing us closer to potentially delivering an optimal therapeutic solution effective for both patients and caregivers."

For More Information on BioXcel Therapeutics, Inc (BTAI), Click Here.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.wallstreetnation.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.wallstreetnation.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of wallstreetnation.com) and Cognetivity Neurosciences Ltd., Winning Media has been paid seventy-five thousand dollars for advertising and marketing services for Cognetivity Neurosciences Ltd. We own ZERO shares of Cognetivity Neurosciences Ltd. Please click here for full disclaimer.

Contact Information:

2818047972
[email protected]

SOURCE: wallstreetnation.com


SHARE ARTICLE